Published: 26 November 2020
Author(s): Shimin Jiang, Jinying Fang, Tianyu Yu, Wenge Li
Issue: April 2021
Section: Letter to the Editor

Diabetic kidney disease (DKD) is the leading cause of end-stage renal disease (ESRD) worldwide. Inhibition of intrarenal renin-angiotensin system (RAS) with angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs) has been part of strategy to slow the progression of DKD [1, 2]. However, evidence of head-to-head trials in such populations regarding the relative efficacies of ACEIs and ARBs is very limited.


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.